Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

Back to Item »

Biotie Axes Agreement to Acquire Newron on Latter’s Loss of Partner for Parkinson Disease Drug

Merck Serono’s decision to hand Phase III safinamide back to Newron constitutes material adverse effect, Biotie claims.

Forward this item to a colleague:


 
   

(Separate multiple addresses by commas)

   

(Separate multiple addresses by commas)

Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »